42 citations,
August 1987 in “Archives of Dermatology” Squaric acid dibutylester led to complete hair regrowth in 28.5% of patients with alopecia areata.
21 citations,
December 2014 in “Clinics in dermatology” Squaric acid dibutylester effectively treats alopecia areata.
15 citations,
March 2008 in “The Journal of Dermatology” Topical squaric acid dibutylester worsened discoid lupus erythematosus in a patient.
12 citations,
May 2016 in “British Journal of Dermatology” A 6-year-old boy's skin condition improved after stopping a specific treatment and starting new medications.
6 citations,
October 2016 in “Pediatric Dermatology” A 6-year-old girl had a rare allergic reaction to a hair regrowth treatment.
5 citations,
January 1995 in “Journal of Dermatological Treatment” Calcipotriol does not improve the effectiveness of squaric acid dibutylester in treating alopecia areata.
3 citations,
January 2014 in “The Journal of Dermatology” Squaric acid dibutylester for alopecia areata can cause benign skin lymphoid growths.
1 citations,
June 2019 in “Journal of Cutaneous Immunology and Allergy” Squaric acid dibutylester can cause severe skin reactions in people with allergies.
275 citations,
November 2002 in “International Journal of Dermatology” Alopecia areata mainly affects young people and has significant psychological impacts, especially in males.
60 citations,
September 2001 in “British journal of dermatology/British journal of dermatology, Supplement” Topical contact sensitizers can treat certain skin conditions by changing the immune response.
48 citations,
June 2003 in “Journal of Investigative Dermatology Symposium Proceedings” Contact sensitizers like DCP and SADBE are the most effective treatments for alopecia areata.
45 citations,
January 2010 in “International journal of trichology” Topical immunotherapy, especially with DPCP, is effective for treating severe alopecia areata.
44 citations,
April 2017 in “International Journal of Dermatology” No treatment is completely effective for alopecia totalis and alopecia universalis.
41 citations,
February 2001 in “Current pharmaceutical design” Current and future treatments for alopecia areata focus on immunosuppression, immunomodulation, and protecting hair follicles.
23 citations,
July 2008 in “British journal of dermatology/British journal of dermatology, Supplement” Topical contact sensitizers can treat certain skin conditions but are rarely used in the U.K.
18 citations,
April 2010 in “Archives of Dermatology” Psoriasis or contact dermatitis can override alopecia areata, allowing hair growth.
15 citations,
January 2015 in “Dermatitis” Topical immunotherapy is the best treatment for severe alopecia areata.
14 citations,
January 1985 in “International Journal of Dermatology” The cause of alopecia areata was unknown, and while various treatments existed, no best treatment was agreed upon.
November 2000 in “Current problems in dermatology” New treatments for hair loss and excessive hair growth show promise with few side effects and advancements in laser technology.
April 2020 in “Trends in Immunotherapy” Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
Lasers and light therapy are effective for treating skin conditions like hair loss, vitiligo, psoriasis, and molluscum contagiosum.
July 2003 in “Journal of Cutaneous Medicine and Surgery” Minoxidil may improve hair transplants and combining treatments could help alopecia areata.
January 1989 in “Handbook of experimental pharmacology” Drugs can change hair growth and this is important because it can upset people.
2 citations,
July 2014 in “Our Dermatology Online” Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.
1 citations,
June 2018 in “International Journal of Dermatology” DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
132 citations,
November 1998 in “Journal of the American Academy of Dermatology” Topical sensitizers have mixed success in treating alopecia areata.
71 citations,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.
September 2022 in “Dermatology and therapy” Contact immunotherapy might help treat various skin conditions, but more research is needed to confirm its safety and effectiveness.
27 citations,
January 2005 in “American Journal of Clinical Dermatology” Azelaic acid and anthralin are similarly effective for treating patchy hair loss.
51 citations,
September 2015 in “Medical Clinics of North America” The conclusion is that acne, alopecia, and hyperhidrosis are common skin issues with various treatments available, and accurate diagnosis is key for effective management.